Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

NCT01587040
completedphase_1

A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

NCT01943838
completedphase_1

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

NCT01392924
completedphase_1

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

NCT01436565

Clinical Trials (4)

Showing 4 of 4 trials
NCT01587040Phase 1

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

Completed
NCT01943838Phase 1

A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma

Completed
NCT01392924Phase 1

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

Completed
NCT01436565Phase 1

A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4